Skip to main content

SAFE-N-MEDTECH, a new European H2020 NMBP (Nanotechnologies, Advanced Materials, Biotechnology and Advanced Manufacturing and Processing) medtech project, has been launched. BioWin has joined this project as a third party through the Council of European BioRegions (CEBR).

OBJECTIVE
This is an opportunity to integrate a future hub of more than 30 medtech partners. BioWin will contribute to the hub’s dissemination and creation.

ACTIONS
SAFE-N-MEDTECH will build an innovative open access platform providing reference laboratories and companies with the capabilities, know-how, networks and services needed for developing, testing, evaluating, optimizing and marketing nanotechnology and diagnostic medical devices throughout the products’ entire lifecycle.

This platform will give SMEs, healthcare providers and industries a novel, multi-disciplinary, market-driven approach based on in-depth understanding and knowledge of materials, property, advanced uses and applications in the medtech sector.

PARTNERS
Spain (leader)
Norway
Colombia
Romania
Belgium
Italy
France
Ireland
United Kingdom
Norway
Portugal
Germany
Netherlands
China